Edwards Lifesciences Corp (NYSE:EW) VP Huimin Wang sold 3,800 shares of the stock in a transaction that occurred on Thursday, December 6th. The stock was sold at an average price of $155.87, for a total value of $592,306.00. Following the sale, the vice president now directly owns 35,024 shares of the company’s stock, valued at $5,459,190.88. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Huimin Wang also recently made the following trade(s):

  • On Tuesday, November 6th, Huimin Wang sold 33,800 shares of Edwards Lifesciences stock. The stock was sold at an average price of $150.43, for a total value of $5,084,534.00.
  • On Friday, October 5th, Huimin Wang sold 3,800 shares of Edwards Lifesciences stock. The stock was sold at an average price of $152.79, for a total value of $580,602.00.

Shares of EW traded down $6.12 during mid-day trading on Friday, hitting $157.21. 1,160,272 shares of the company’s stock were exchanged, compared to its average volume of 1,353,565. The stock has a market capitalization of $34.14 billion, a P/E ratio of 41.37, a P/E/G ratio of 2.15 and a beta of 0.90. Edwards Lifesciences Corp has a 52 week low of $110.68 and a 52 week high of $175.00. The company has a quick ratio of 1.85, a current ratio of 2.31 and a debt-to-equity ratio of 0.18.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, October 23rd. The medical research company reported $1.07 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.05. The company had revenue of $906.60 million during the quarter, compared to analysts’ expectations of $927.56 million. Edwards Lifesciences had a net margin of 20.67% and a return on equity of 30.11%. The business’s quarterly revenue was up 10.4% on a year-over-year basis. During the same period last year, the business earned $0.84 EPS. On average, sell-side analysts anticipate that Edwards Lifesciences Corp will post 4.7 earnings per share for the current fiscal year.

EW has been the subject of a number of research reports. Zacks Investment Research raised Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $185.00 target price for the company in a research note on Wednesday, September 26th. Bank of America cut Edwards Lifesciences from a “buy” rating to a “neutral” rating in a research note on Tuesday, October 2nd. Guggenheim cut Edwards Lifesciences from a “buy” rating to a “neutral” rating in a research note on Tuesday, October 2nd. Northland Securities reissued a “hold” rating and set a $120.00 target price on shares of Edwards Lifesciences in a research note on Thursday, October 11th. Finally, SunTrust Banks increased their target price on Edwards Lifesciences to $200.00 and gave the stock a “buy” rating in a research note on Friday, September 28th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $162.85.

Several institutional investors and hedge funds have recently modified their holdings of the company. Raymond James Financial Services Advisors Inc. lifted its stake in Edwards Lifesciences by 36.5% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 12,442 shares of the medical research company’s stock worth $1,811,000 after purchasing an additional 3,327 shares in the last quarter. Alps Advisors Inc. purchased a new position in Edwards Lifesciences in the 2nd quarter worth approximately $463,000. TD Asset Management Inc. raised its position in shares of Edwards Lifesciences by 2.9% during the 2nd quarter. TD Asset Management Inc. now owns 82,295 shares of the medical research company’s stock valued at $11,980,000 after buying an additional 2,328 shares during the period. First Trust Advisors LP raised its position in shares of Edwards Lifesciences by 633.6% during the 2nd quarter. First Trust Advisors LP now owns 364,884 shares of the medical research company’s stock valued at $53,116,000 after buying an additional 315,144 shares during the period. Finally, LMR Partners LLP raised its position in shares of Edwards Lifesciences by 133.3% during the 2nd quarter. LMR Partners LLP now owns 4,508 shares of the medical research company’s stock valued at $656,000 after buying an additional 2,576 shares during the period. 82.55% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Huimin Wang Sells 3,800 Shares of Edwards Lifesciences Corp (EW) Stock” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://www.watchlistnews.com/huimin-wang-sells-3800-shares-of-edwards-lifesciences-corp-ew-stock/2670469.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Featured Article: How to invest in a bear market

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.